NXL-004 is an innovative treatment approach developed based on Professor Chen Gong’s pioneering in situ differentiation technology platform. It is notably the first AAV gene therapy product for malignant glioblastoma to receive FDA orphan drug designation. The therapy targets glioblastoma cells by overexpressing the neurogenic transcription factor NeuroD1, inhibiting tumor cell proliferation while promoting their differentiation into neurons. This mechanism offers potential advantages over conventional treatments such as radiotherapy and chemotherapy, with minimal side effects on surrounding tissues.
The initial patient, suffering from recurrent glioblastoma, underwent surgery and dosing without complications. Postoperative observations revealed a stable condition with no significant adverse reactions, culminating in a smooth recovery and discharge within a week. This successful administration of AAV-NeuroD1 gene therapy represents a groundbreaking leap from preclinical research to clinical application, offering hope for improved treatment outcomes in glioblastoma patients.
Professor Huang Yulun expressed optimism regarding the therapy’s safety and efficacy, citing promising preclinical data and the favorable safety profile observed in the first clinical trial subject. Likewise, Professor Chen Gong, the founder of NeuExcell Therapeutics, commended Professor Huang Yulun’s team for their collaboration and surgical expertise, underscoring the significance of this milestone in advancing neurological disease treatments.
The successful dosing of NXL-004 at Suzhou Dushu Lake Hospital underscores the potential of gene therapy in revolutionizing the management of malignant glioblastoma, addressing the urgent need for more effective treatment options in neuro-oncology. This achievement serves as a testament to the collaborative efforts of researchers and medical professionals in pushing the boundaries of medical science for the benefit of patients worldwide.
https://mp.weixin.qq.com/s/sOHG3tioxVxfwTRKWBSejQ
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Groundbreaking Intravenous Gene Therapy Offers New Hope for Metachromatic Leukodystrophy Patients
A recent study conducted by researchers from the TIDU GENOV at the Institut du Cerveau in Paris, France, presents promising results for the treatment of Metachromatic Leukodystrophy (MLD), a severe neurodegenerative disease. Led by Emilie Audouard with key...
Astellas’ Friedreich’s ataxia gene therapy cleared for clinical study after earlier version stumbled
After hitting a speed bump in its first attempt at developing a gene therapy for Friedreich’s ataxia, Astellas is ready to put a new version in the clinic. On Thursday, the Japanese drugmaker announced the FDA has cleared its IND for ASP2016. The company is hoping to...
Autolomous and BioCentriq Partner to Speed Up Cell Therapy Delivery
Collaboration leverages cutting-edge digital platform to streamline development and manufacturing activities and speed patient access to life-changing treatmentsLONDON and NEWARK, N.J., April 24, 2024 /PRNewswire/ -- Autolomous, the market-leading developer of...
Study reviews the role of a ribonucleic acid ‘MALAT1’ in hematological malignancies
Recent studies have shown that an abnormally high expression of MALAT1 in blood cancer cells could aid the chemotherapeutic resistance development through multiple intermolecular interactions. Although researchers first identified the role of MALAT1 in patients with...
Related Services
Plasmids GMP Services
AAV GMP Services
